Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: A report of two cases

Rheumatology International

Volumn 33, Issue 6, 2013, Pages 1643-1644

  Besada, Emilio ^a,b   Bader, Lucius ^b   Nossent, Hans ^b,c  

^a Revmatologisk Avdeling   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Common variable immunodeficiency; Granulomatosis with polyangiitis; Hypogammaglobulinemia; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; ATELECTASIS; B LYMPHOCYTE; BACTERIAL PNEUMONIA; CASE REPORT; COMMON VARIABLE IMMUNODEFICIENCY; DYSPNEA; FEMALE; GRANULOMATOSIS; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; INFLUENZA B; LEUKOPENIA; LYMPHOCYTE; MAINTENANCE THERAPY; MALE; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; NEUTROPHIL; PRIORITY JOURNAL; REMISSION; STAPHYLOCOCCAL PNEUMONIA;

ADULT; AGAMMAGLOBULINEMIA; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; INFECTION; MALE; RISK; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84878697688     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2353-5     Document Type: Article

References (8)

1. Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149:3-13
2. Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Jt Bone Spine 78:241-245
3. Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M et al (2005) Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 75:527-529
4. Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J et al (2008) Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 26:431-433
5. Furst DE (2008) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18-29
6. Rees F, Yazdani R, Lanyon P (2011) Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol 30:1241-1245
7. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B et al (2010) on behalf of the investigators of the autoimmunity and rituximab registry and the French Society of Rheumatology. risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62:2625-2632
8. Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F et al (2010) Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63:275-277